Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The first complete DBS system with sensing, directionality, and visual programming, giving you access to the data-driven insights you need to make informed decisions.Download brochure
When paired with the Percept™ PC device, the SenSight™ directional lead expands BrainSense™ technology* – delivering patient-specific therapy using physiological sensing data that facilitates confident, informed therapy decisions.
The Percept™ PC neurostimulator with BrainSense™ technology* is designed to capture a patient's brain signals, providing clinicians objective data directly from a DBS patient's brain to understand the impact of treatment decisions such as medication or stimulation changes.
BrainSense™ technology captures brain signals (local field potentials, or LFPs) using the implanted DBS lead. These signals can be recorded simultaneously while delivering therapeutic stimulation, inside and outside the clinic.* Clinicians can also correlate these brain signals with stimulation and patient-captured events such as medication, symptoms, or side effects.
See electrode-level comparisons — between
segmented levels, among segments within each
level, and in each direction between the two levels.
Ergonomically designed, the Percept™ PC
device offers enhanced comfort for patients.
* In overall device volume.
† Refers to case thickness.
The first 3T and 1.5T MR Conditional‡ DBS
system with a directional, sensing lead
The Percept™ PC device offers improved longevity††
and features smart battery technology**
The DBS patient programmer is enhanced so patients can more easily and conveniently engage with their therapy.
‡ Medtronic DBS systems are MR Conditional and safe in the MR environment as long as certain conditions are met. If the conditions are not met, a significant risk is tissue lesions from component heating, especially at the lead electrodes, resulting in serious and permanent injury including coma, paralysis, or death. Refer to the MRI Guidelines for Medtronic Deep Brain Stimulation Systems for a complete list of conditions. Refer to the MRI Guidelines for Medtronic Deep Brain Stimulation Systems at www.medtronic.com/mri or contact Medtronic at 800-328-0810 for a complete list of conditions.
** Based on current actual battery level and therapy settings from last seven days.
†† For median energy use in DBS for patients with Parkinson’s disease, with moderate (up to two months per year) BrainSense™ technology usage.
The Percept™ PC device features BrainSense™ technology*, designed to capture brain signals (local field potentials, or LFPs) using the implanted DBS lead. These signals can be recorded simultaneously while delivering therapeutic stimulation, inside and outside the clinic.
You can correlate these brain signals with stimulation and events capturing medication, symptoms, or side effects — to deliver personalized, data-driven treatment and adjust as patient needs evolve.*
OptiStim™ control allows you to assign unique amplitude values to each electrode. Add or subtract segments from the configuration without dropping amplitude of all electrodes to zero (in unipolar mode).
After achieving desired stimulation shape with OptiStim™ control, use ShapeLock™ control to seamlessly increase or decrease the shape created — an intuitive interface for advanced programming needs.
Select a pair of rates and assign any electrode across the two leads to one of the two rates.
Assign different rates by electrode — to electrodes in different hemispheres or to different electrodes on the same lead.
The sensing feature of the Percept™ PC device is intended for use in patients receiving DBS where chronically recorded bioelectric data may provide useful, objective information regarding patient clinical status. Signal may not be present or measurable in all patients. Clinical benefits of brain sensing have not been established.
Neumann WJ, Staub F, Horn A, et al. Deep brain recordings using an implanted pulse generator in Parkinson’s disease. Neuromodulation. 2016;19(1):20–24.